Background {#Sec1}
==========

Our group's systematic analysis of the published literature of randomised controlled trials (RCTs) in veterinary homeopathy identified 38 peer-reviewed papers that we regarded as potentially eligible for detailed review \[[@CR1]\]. As emphasised in that article, no systematic review of this research evidence had ever previously been carried out.

We have recently reported our review findings for 18 placebo-controlled trials of veterinary homeopathy \[[@CR2], [@CR3]\], in which there was indecisive evidence whether the use of homeopathy in animals is distinguishable from placebos. The present paper reports our results from a similarly detailed appraisal and analysis of the remaining papers, each of which reported an RCT where the control group was an intervention other than placebo (OTP).

Our approach here reflects our original literature analysis \[[@CR1]\] and so we continue to distinguish peer-reviewed from non-peer-reviewed articles, individualised from non-individualised homeopathy, and treatment from prophylaxis. We thus report our findings from the appraisal of peer-reviewed, OTP-controlled trials of veterinary homeopathy (individualised or non-individualised, treatment or prophylaxis).

Our objective firstly was to assess the study quality (risk of bias) of each eligible RCT \[[@CR4]\], together with the direction and statistical significance of treatment or prophylactic effect. For suitable groupings of RCTs (per species-specific medical condition; per type of control group), we aimed then to determine pooled summary statistics by meta-analysis methods and to examine their sensitivity to study quality. In both objectives, our emphasis was focused on trials that satisfied our criteria for reliable evidence \[[@CR2], [@CR3]\].

Methods {#Sec2}
=======

Methods comply with the *PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)* 2009 Checklist (see Additional file [1](#MOESM1){ref-type="media"}) \[[@CR5]\]. They are compatible with our previously published papers in this series of veterinary reviews \[[@CR1]--[@CR3]\], and with our protocol-based systematic reviews and meta-analyses of homeopathy RCTs in human medicine \[[@CR6], [@CR7]\].

Matters connected with study eligibility, research design categories and the literature search strategy were described in detail in our earlier paper \[[@CR1]\]. Only brief descriptions are therefore given here, with additional information that is specific to the methods used for the present paper.

Identifying papers for full data extraction {#Sec3}
-------------------------------------------

Each of the following electronic databases was searched up to and including March 2011 \[[@CR1]\], with a follow-up search of the same databases up to the end of 2013: *AMED*, *CINAHL*, *CENTRAL*, *Embase*, *HomVetCR*, *LILACS*, *PubMed*, *Science Citation Index*, *Scopus*. There were no language restrictions. During the peer-review process for the current paper, we became aware that relevant additional literature might be contained in *CAB Abstracts* \[[@CR8]\], which we therefore searched up to and including May 2015, and with the intention to update our review and analysis if significant numbers of eligible RCTs were revealed.

In our original literature search \[[@CR1]\], 20 records of trials were identified as satisfying the key acceptance criteria for the present systematic review: substantive report of clinical treatment or prophylaxis trial for any medical condition or species in veterinary homeopathic medicine, randomised, controlled by OTP, and published in a peer-reviewed journal. One of us screened and categorised each of these potentially relevant papers (plus those identified in our follow-up search -- see *Results*) to assess their eligibility for full data extraction. The other independently appraised these decisions; any differences of opinion were resolved by consensus discussion.

### Exclusion criteria prior to full data extraction {#Sec4}

Research using radionically prepared 'homeopathic' medicines.The tested intervention is homeopathy combined with other (complementary or conventional) medicine or therapy.

Data extraction and management {#Sec5}
------------------------------

The authors of eligible RCT papers were not approached for clarification on unclear or missing facets of their methods or results \[[@CR4]\], though original authors' cross-reference to their previously published study methods were taken into account as appropriate \[[@CR2]\]. For each of two assessors working independently, relevant data were extracted and then recorded using a standardised data collection format (Microsoft *Excel*).

No paper reported more than one RCT. For a paper reporting an RCT that involved \>2 groups of subjects, we typically pursued data extraction on *only one pair of groups*: trials that included an OTP as well as a placebo control group had been scrutinised previously \[[@CR2], [@CR3]\] and were not reappraised for the current study. For studies that comprised \>1 homeopathy group, the total sample size reflects the total numbers of subjects in the homeopathy groups *combined* \[[@CR9]\]. This was the approach in all relevant cases, i.e.: where the same homeopathic medicine was used, and with the same timing of administration but in different potency; where the same homeopathic medicine and potency was used, but with different timing of administration; where a different homeopathic medicine was used.

Study appraisal {#Sec6}
---------------

### Assessment of risk of bias {#Sec7}

Using the standard criteria defined by Cochrane \[[@CR4]\], extraction of information from each paper enabled us to answer the question, 'Is the study free from risk of bias?': 'Yes'; 'Unclear'; 'No'. The two assessors' independent judgments were mutually scrutinised and compared, with discrepancies between them resolved by consensus discussion. This approach applied to each of seven assessment domains: I, the method used to generate the random sequence; II, the method of allocation concealment used to implement the random sequence; IIIA, the blinding of trial personnel, including animal owner as appropriate; IIIB, the blinding of outcome assessors; IV, whether all the randomised patients are accounted for in the analysis; V, whether there is evidence of selective outcome reporting; VI, whether there is evidence of other bias, such as extreme data imbalance at baseline.

For domain IV, a trial was automatically regarded as no better than 'unclear' if there was greater than 20 % participant attrition rate, irrespective of whether intention-to-treat analysis had been carried out on the data. For domain V, we based our judgment of reported outcomes on a comparison with the details given in the same paper's *Methods* section (original trial protocols have not been published in veterinary homeopathy). For the purposes of the current paper, we assessed domain V as 'No' (high risk of bias) if the main outcome data were not extractable for meta-analysis. The source of any research funding/sponsorship, or other vested interest such as personnel employment or contract, was not taken into account for risk-of-bias assessment (domain VI), but was reflected in the overarching assessment of risk of bias for each RCT.

### Assessment per trial for risk of bias {#Sec8}

Using the Cochrane approach \[[@CR4]\], each trial was designated overall as follows: low risk of bias for all domains; uncertain risk of bias for one or more domains, and no evident risk of bias in any domain; high risk of bias for one or more domains. A trial with overall low risk of bias comprised reliable evidence. For a trial that did not display high risk of bias in any domain, we regarded its evidence as reliable if the study was assessed as free of bias for each of domains I, IIIA, IIIB and IV \[[@CR2], [@CR3]\].

Outcome assessment and reporting {#Sec9}
--------------------------------

### Identification of 'main outcome measure' per trial {#Sec10}

For the purposes of risk-of-bias assessment and for assessment of treatment effect, we identified for each trial a single 'main outcome measure' using a refinement of the approaches adopted by Linde et al. \[[@CR10]\] and by Shang et al. \[[@CR11]\]. The main outcome measure of each trial was based on a hierarchical ranking order (consistent with the World Health Organization's \[[@CR12]\] classification system for levels of functioning linked to health condition), and as previously described \[[@CR2]\]. This approach ensured that the most clinically important outcome was selected per trial, and also avoided the problem of outcome multiplicity \[[@CR13]\].

Unless otherwise indicated, the single end-point (as determined from the start of the intervention) associated with the designated 'main outcome measure' was taken as the last follow-up at which data were reported for that outcome \[[@CR2]\].

Analysis of outcomes {#Sec11}
--------------------

### Summary effect measures for 'main outcome' {#Sec12}

For each eligible trial, the effect size was taken as the difference between the homeopathy group and the control group at the designated end-point of the trial, as follows \[[@CR2]\]:For a dichotomous measure: odds ratio (OR), with 95 % confidence interval (CI);For a continuous measure: standardised mean difference (SMD), with 95 % CI.

If the original paper did not provide adequate information on the designated main outcome measure to enable data extraction, that trial's outcome was classified as 'not estimable' and a further potentially estimable outcome was not sought.

Under the separate group headings of *individualised homeopathy* and *non-individualised homeopathy*, and for the categories below in which there was \>1 RCT of a given study design that had extractable data, we aimed to determine pooled summary statistics for:Disease-specific treatment effects per species;Disease-specific prophylactic effects per species.

All calculations and analyses were performed using *Review Manager 5.2* (Cochrane). Given our anticipation of heterogeneous data for intervention effects, the random-effects (rather than fixed-effects) model was planned for all meta-analyses \[[@CR14]\].

### Reflecting study quality overall {#Sec13}

Our main analyses used only the data extracted from trials without evident high risk of bias. It was intended that our primary conclusions would be based solely on trials with reliable evidence and without overt vested interest (not funded, directly or indirectly, by a homeopathic pharmacy).

Direction of effect of treatment/prophylaxis per trial {#Sec14}
------------------------------------------------------

Care was taken faithfully to represent the correct direction of change per trial: e.g. an effect favouring homeopathic intervention was *higher* rate of recovery but *lower* faecal egg count. The arithmetic content of the OR, or the sign of the SMD, was adjusted appropriately if so indicated.

We regarded each RCT as a *superiority trial* \[[@CR15]\] unless the original paper stated explicitly in its *Methods* section that the study was designed as an equivalence or non-inferiority trial \[[@CR16], [@CR17]\], with corresponding power calculation. For each of three study designs (and regarding each design as a superiority trial), we adopted the following rationale for interpretation of the three possible statistical findings:

Statistical finding (i): *P* ≤ 0.05: Direction of effect toward homeopathy*Study design: active control.* Homeopathy is more effective than a conventional intervention;*Study design: \[homeopathy plus active control\]* versus *active control ('\[A + B\]* versus *B').* Homeopathy combined with conventional intervention is more effective than conventional intervention alone;*Study design: no-treatment control.* Homeopathy is more effective than no intervention.

Statistical finding (ii): *P* ≤ 0.05: Direction of effect toward control*Study design: active control.* Homeopathy is less effective than a conventional intervention;*Study design: \[homeopathy plus active control\]* versus *active control ('\[A + B\]* versus *B').* Homeopathy combined with conventional intervention is less effective than conventional intervention alone;*Study design: no-treatment control.* Homeopathy is ineffective.

Statistical finding (iii): *P* \> 0.05: Direction of effect toward either homeopathy or control*Study design: active control.* Inconclusive whether homeopathy is more or is less effective than a conventional intervention \[[@CR18], [@CR19]\];*Study design: \[homeopathy plus active control\]* versus *active control ('\[A + B\]* versus *B').* Inconclusive whether homeopathy combined with conventional intervention is more or is less effective than conventional intervention alone;*Study design: no-treatment control.* Inconclusive whether homeopathy is more or less effective than no treatment.

Results {#Sec15}
=======

Demographic details {#Sec16}
-------------------

Additional file [2](#MOESM2){ref-type="media"} illustrates the *PRISMA* flowchart, which follows on from, and suitably updates \[[@CR20]\], that in our earlier paper \[[@CR1]\]; our current focus is on OTP-controlled trials only. Two OTP-controlled trials were rejected from the current review due to their focus on homeopathy combined with another intervention: A29, Dreissman 2010; A30, Lepple 1984. A further two were excluded due to their focus on neither treatment nor prophylaxis: A33, Sharma 1987; A37, Trehan 1994. Four additional eligible records were identified in our follow-up search, and included in analysis. Our subsequent search of *CAB Abstracts*, conducted during peer review of the current paper, revealed just one potentially eligible trial \[[@CR21]\], which we did not consider further.

Table [1](#Tab1){ref-type="table"} details each of the 20 studies eligible for full systematic review: (i) individualised homeopathy/treatment (n = 1); (ii) non-individualised homeopathy/treatment (n = 13); (iii) non-individualised homeopathy/prophylaxis (n = 6). Data per trial include: nature of the homeopathic intervention; study setting; the RCT's source of funding. Our definitions of 'treatment' and 'prophylaxis' were as previously described \[[@CR1]\]. All RCTs were identified as superiority trials, despite the fact that in some cases the original authors applied the terms 'equivalence trial' or 'non-inferiority trial' *post-hoc* in *Results* or in *Discussion* (A15, Faulstich 2006; A39, Braun, 2011).Table 1Demographic details of 20 OTP-controlled RCTs in veterinary homeopathy**i: Individualised/TreatmentConditionSpeciesRef.First authorYearDesignControlHomeopathic medicineDilution\*Study settingFundingFree from vested interest**Mastitis, metritis and agalactiaPigsA12Schütte1988ActiveAntibioticIndividualisedD3-D12University veterinary ambulance; 21 swine herds in Germany (Berlin area)Remedies were gift of the manufacturerNo**ii: Non-individualised/TreatmentConditionSpeciesRef.First authorYearDesignControlHomeopathic medicineDilutionStudy settingFundingFree from vested interest**Diarrhoea (neonatal)CattleA42Lohr2012ActiveOral electrolytes3 complex preparations: Nux vomica; Veratrum; EngystolNot statedSix farms in GermanyDirectly funded study (Heel Pharmacy)NoDiarrhoea (neonatal)PigsA14Coelho2009ActiveAntibioticPhosphorus/E. coli30CSwine farm, BrazilThe company, Farmácia Sensitiva, \'supplied\' the medicinesNoEctoparasite infestationCattleA41Catto2013ActiveAnthelmintic2 complex preparations of various components (mainly nosodes)All but one components potentised to 12C and higher (30C, 200C)Cattle farm, BrazilNone statedUnclearEctoparasite infestationCattleA19Silva2008ActiveChemical dipBiotherapic\' of Boophilus microplus and 14 other organisms12CGovernment research institution, BrazilNone declared\'. The homeopathic laboratories, Flora & Fauna Ltd., supplied the medicineNoFoot-and-mouth diseaseCattleA40Lotfollahzadeh2012ActiveAnti-inflamatory and antibioticTarentula cubensisD5Cattle farms, IranRichter Pharma donated the homeopathic medicineNoGastrointestinal nematodesSheepA21Zacharias2008ActiveAnthelmintic3 remedies: Ferrum phosphoricum, Arsenicum album, Calcarea carbonicaNot statedGovernment research institution, BrazilNone statedUnclearLamenessHorsesA15Faulstich2006ActiveHyaluronic acidComplex of 14 homeopathically prepared ingredientsD3 - D8Two horse clinics in Germany (Berlin area, Munich area)Study performed by a contract research organisationNoMastitisCattleA16Klocke2010ActiveTeat-sealer8 remedies: Mercurius solubilis, Lachesis mutus, Sulfur, Calcium carbonicum, Calcium phosphoricum, Pulsatilla pratensis, Sepia, SilicaD6Thirteen organic dairy herds, SwitzerlandEC grant; Weleda \'provided the remedies\'NoMastitisCattleA20Varshney2005ActiveAntibioticComplex of 8 remedies: Healwell VT-6 (Sintex International Limited, Kalol, India), consisting of Phytolacca, Calcarea fluorica, Silica, Belladona, Bryonia, Arnica, Conium, Ipecacuanha \"in equal amount\"200C: Phytolacca, Calcarea fluorica. 30c: Silica, Belladona, Bryonia, Arnica, Conium, IpecacuanhaDairy farm, IndiaSintex International Ltd \'supplied the homeopathic formulation for clinical trial\'NoMastitis, metritis and agalactiaPigsA39Braun2011ActiveAntibiotic2 complex preparations. Lachesis compositum + TraumeelNot statedThree piglet-rearing farms in GermanyDirectly funded study (Heel Pharmacy)NoPseudopregnancyDogsA13Beceriklisoy2008ActiveNaloxoneThuja occidentalis/Urtica urensD30University animal clinic, TurkeyNone statedUnclearSalmonellosisBirdsA18Sandoval1998ActiveAntibioticBaptisia tinctoria30CPoultry farm, MexicoNone statedUnclearGastrointestinal nematodesSheepA17Rocha2006(A + B) vs. BAnthelmintic onlyFator VermesNot statedUniversity establishment, BrazilNone statedUnclear**iii: Non-individualised/ProphylaxisConditionSpeciesRef.First authorYearDesignControlHomeopathic medicineDilutionStudy settingFundingFree from vested interest**Ectoparasite infestationCattleA34Signoretti2008(A + B) vs. BProtein supplement onlyFactor C & MC ® : 16 remediesAll 12CGovernment research institution, BrazilNone statedUnclearDiarrhoea (neonatal)PigsA36Soto2008(A + B) vs. BSucrose saline onlyComplex of 4 remedies: Echinacea angustifolia, Avena sativa, Ignatia amara, and Calcarea carbonica6CCommercial swine herd, BrazilNone statedUnclearHandling stressCattleA31Reis2006(A + B) vs. BMineral salt onlyMatricaria chamomilla®12C (plus non potentised sugar and Bixa orellana \[grams\])Cattle farm, Brazil\"This research was supported by the Homeopathic Laboratory Arenales Flora & Fauna Ltd.\"NoImmune response to rabies vaccinationCattleA32Reis2008(A + B) vs. BMineral salt onlyMatricaria chamomilla®12CCattle farm, BrazilThe homeopathic laboratories, Flora & Fauna Ltd., are thanked by the author non-specificallyUnclearInfertilityCattleA35Sommer1972Un-treatedUntreatedComplex of 5 remediesD3-D5Two cattle farms, University of Hohenheim (Germany)None statedUnclearInfertilityCattleA38Williamson1991Un-treatedUntreatedSepia200CDairy herd, ScotlandBritish Cattle Veterinary Association. The pharmacy, Ainsworth\'s, are thanked by the authors non-specificallyUnclear\**Note on homeopathic dilutions:* The number refers to the number of successive serial dilutions to which the starting material has been subjected. The letter refers to the scale on which the dilution has been carried out: the letter D denotes the decimal method of dilution (that is, one part of liquid is added to nine parts of purified water, ethanol, glycerol or lactose); the letter C indicates the centesimal method (one part added to 99 parts of diluent). In homeopathic dilutions above 12C/D24 (10^−24^ molar) -- beyond Avogadro's constant, 6.02 x 10^23^ mol^−1^ -- there are, in theory, no material traces of the original substance; such dilutions are known as 'ultra-molecular'

Extreme diversity characterised the studies as regards species, medical condition, homeopathic medicine, and funding source. In the 20 eligible studies, 6 different species are represented: birds (n = 1); cattle (n = 11); dogs (n = 1); horses (n = 1); pigs (n = 4); sheep (n = 2). Twelve different conditions are represented. None of the trials had a clearly unbiased funding source; we identified overt vested interest in 10 of the 20 trials.

Table [2](#Tab2){ref-type="table"} includes: sample sizes; designated 'main outcome measure'; type of data (whether dichotomous or continuous); study endpoint. Diversity was again apparent, with large variation in sample sizes, main outcome, and timing of the study endpoint.Table 2Sample sizes and outcomes for 20 OTP-controlled RCTs**i: Individualised/TreatmentRef.First authorYearN start (hom.)N start (cont.)N start (tot.)N end (hom.)N end (cont.)N end (tot.)% AttritionDesignated \'main outcome\'Type of dataDirection of change favouring homeopathyProblem with designated \'main outcome measure\'End-pointNotes**A12Schütte19883331643331640.0Piglet mortalityDichot.LowerYes: Gives percentage of dead piglets (events) but not number of piglets born (total)28 dN = No. of sows treated**ii: Non-individualised/TreatmentRef.First authorYearN start (hom.)N start (cont.)N start (tot.)N end (hom.)N end (cont.)N end (tot.)% AttritionDesignated \'main outcome\'Type of dataDirection of change favouring homeopathyProblem with designated \'main outcome measure\'End-pointNotes**A42Lohr2013535610946541008.3Cure rate (Sum-score (physical condition))Dichot.HigherOnly 46 (Hom) and 54 (Cont) animals regularly completed the study, and are therefore the data for our calculations. The authors themselves calculated cure rate based on 50 and 56 animals respectively.Up to 4 dA14Coelho2009351146359444.3Proportion of animals without diarrhoea at the end of treatmentDichot.HigherNo12 dA41Catto2013723610872361080.0Faecal egg countContin.LowerYes: Unclear sample sizes -- see NotesSecond yearThe numbers of animals in each group based on the assumption that each group comprised 3 paddocks (12 animals in each). No information on dropouts.A19Silva20089918?9?9?18UnclearMean number of engorged ticks per annumContin.LowerYes: SD not stated; N at endpoint not stated1 yrA40Lotfollahzadeh201252237550156513.3Rectal temperatureContin.Lower14 dA21Zacharias20087714?7?7?14UnclearFaecal egg countContin.LowerNo. Numbers for analysis interpolated from Figure [1A](#Fig1){ref-type="fig"}. N not stated for endpoint, but assumed to be N = 7.68 dDisparity between data (mean eggs per gram) for conv med group given in text (1,483) and by inspection of Fig [1](#Fig1){ref-type="fig"} (1,300 approx.)A15Faulstich200624224622194110.9Treatment success (overall effectiveness)Dichot.HigherNo : Numbers for analysis from percentage data in Table 921 dControl really active?A16Klocke20103236683236680.0Absence of clinical mastitis infectionDichot.HigherNo: Data derived from text of Results \[line 6\])First 100 days post-calvingA20Varshney2005679616367961630.0Quarter cure-rate (non-fibrosed)Dichot.HigherNo : Numbers for analysis from percentage data in Table 2Up to 28 dN = quarters, not animalsA39Braun20113034642832606.3Cure rate (MMA-sum score)Dichot.HigherUp to 4 d (H) or 3 d (C)A13Beceriklisoy200830838308380.0Treatment \'success\' (recovery rate)Dichot.HigherNoUp to 20 dA18Sandoval19982002004002002004000.0Cumulative total mortality (1st quality broilers)Contin.LowerYes: Data are presented as accumulated mortality -- not amenable to meta-analysis49 dN = 1st quality broilersA17Rocha20061010201010200.0Proportion of animals not requiring anti-helminthic treatmentDichot.HigherNo: Data derived from text of Results (second paragraph)4 mo (first phase)**iii: Non-individualised/ProphylaxisRef.First authorYearN start (hom.)N start (cont.)N start (tot.)N end (hom.)N end (cont.)N end (tot.)% AttritionDesignated \'main outcome\'Type of dataDirection of change favouring homeopathyProblem with designated \'main outcome measure\'End-pointNotes**A34Signoretti20088816?8?8?16UnclearFaecal egg count per gramContin.LowerNo. But assumes zero attrition rate. Data from Table [3](#Tab3){ref-type="table"}.30 dA36Soto20082424482424480.0Number of animal-days with diarrhoeaDichot.LowerNo. But relate 7-day cumulated data to total possible number of animal-days per group7d periodHom plus sucrose saline vs. sucrose saline onlyA31Reis20063030603030600.0Serum cortisolContin.LowerNo. Assumes zero attrition rate based on legend for Figure 1.60 dHom plus mineral salt vs. mineral salt onlyA32Reis200815153015?15?30UnclearRabies-neutralizing antibody titerContin.HigherNo. But assumes zero attrition rate.60 d after vaccinationCompares Group FEV2 (Hom + salt) with Group V2 (salt only)A35Sommer19724018584018580.0Number with infertility disordersDichot.LowerNo. Data from table 2Not statedA38Williamson199110132133?100?32?132UnclearNumber with peripartum disordersDichot.LowerYes: Unclear tabulationsNonehom. = homeopathy. cont. = control. tot = total. dichot. = dichotomous. contin. = continuous

Risk of bias {#Sec17}
------------

Table [3](#Tab3){ref-type="table"} shows our risk-of-bias judgments for each eligible trial.Table 3Risk-of-bias assessments for 20 OTP-controlled RCTs**i: Individualised/TreatmentRef.First authorDomain**\
**IDomain**\
**IIDomain**\
**IIIADomain**\
**IIIBDomain**\
**IVDomain**\
**VDomain**\
**VI (excl. fund)No. of domains for which criteria fulfilledRisk of bias (excl. vested interest)Reliable evidence**YUNA12SchütteNNNNYNU115HighNo**ii: Non-individualised/TreatmentRef.First authorDomain**\
**IDomain**\
**IIDomain**\
**IIIADomain**\
**IIIBDomain**\
**IVDomain**\
**VDomain**\
**VI (excl. fund)No. of domains for which criteria fulfilledRisk of bias (excl. vested interest)Reliable evidence**YUNA42LohrYUNYYNN313HighNoA14CoelhoUUNUYYN232HighNoA41CattoUUNUUNU052HighNoA19SilvaUUNUUNU052HighNoA40LotfollahzadehUUNYUNY232HighNoA21ZachariasUUNUUYU151HighNoA15FaulstichYUNYYYY511HighNoA16KlockeYUNUYYY421HighNoA20VarshneyUUUUUYN151HighNoA39BraunYUNYYYN412HighNoA13BeceriklisoyUUUUUYN151HighNoA18SandovalUUUUUNU061HighNoA17RochaNNUUYYU232HighNo**iii: Non-individualised/ProphylaxisRef.First authorDomain**\
**IDomain**\
**IIDomain**\
**IIIADomain**\
**IIIBDomain**\
**IVDomain**\
**VDomain**\
**VI (excl. fund)No. of domains for which criteria fulfilledRisk of bias (excl. vested interest)Reliable evidence**YUNA34SignorettiUUUUUYY250UncertainNoA36SotoUUUUYYU250UncertainNoA31Reis 2006UUUUUYY250UncertainNoA32Reis 2008UUUUUYY250UncertainNoA35SommerUUNUYYU241HighNoA38WilliamsonUUNUUNU052HighNoDomains I-VI are explained in the main text. Criteria fulfilled for domains: Y = Yes; U = Unclear; N = No

Many of the papers were written to such a poor standard that risk-of-bias assessments were sometimes challenging. No trial had low risk of bias in all of the Cochrane judgmental domains. Sixteen trials had high risk of bias in one or more domains. Four trials had merely uncertain risk of bias, and the uncertainty was evident in five domains per study (A31, Reis 2006; A32, Reis 2008; A34, Signoretti 2008; A36, Soto 2008). There was therefore no trial that could be designated as reliable evidence.

Only five of the 20 trials had adequate randomisation (domain I), and none of the trials had adequate allocation concealment (domain II) or personnel blinding (domain IIIA). See also Fig. [1](#Fig1){ref-type="fig"} (*Risk-of-bias summary graph*).Fig. 1Risk-of-bias summary graph**.** Illustrates, for each assessment domain, the proportion of RCTs with low, unclear and high risk of bias

Analysis of outcomes {#Sec18}
--------------------

Fifteen of the 20 trials had extractable data. Due to the diversity of medical conditions, species, types of homeopathic intervention, study designs and outcome measures, as well as the very unclear quality of the evidence, it was not appropriate to carry out meta-analysis on disease-specific intervention.

The direction of effect favoured homeopathy in 11 trials (statistically significantly so in four cases) and favoured control in four trials (statistically significantly so in zero cases) -- see Table [4](#Tab4){ref-type="table"}, in which the inference from the statistical findings is given by reference to the numbered study designs in *Methods: Direction of effect of treatment/prophylaxis per trial*.Table 4Summary statistics for: (a) trials at uncertain risk of bias; (b) trials at high risk of bias**a) UNCERTAIN RISK OF BIASiii: Non-individualised/ProphylaxisRef.First authorYearConditionSpeciesOutcome measureHom.Cont.Summary effect measureEffect size (95 % CI)Direction of change favouring homeopathyDirection of effect*P*** **valueInference**\
**\***A34Signoretti2008Ectoparasite infestationCattleFaecal egg count per gram340 (sd, 214); N = 8207 (sd, 131); N = 8SMD0.71 \[−0.31, 1.73\]LowerCont.0.17\[iii: b\]A36Soto2008Diarrhoea (neonatal)PigsNumber of animal-days with diarrhoea34/19225/192OR0.70 \[0.40, 1.22\]LowerCont.0.20\[iii: b\]*A31Reis2006Handling stressCattleSerum cortisol5.1 (sd, 1.8); N = 305.3 (sd, 1.45); N = 30SMD−0.12 \[−0.63, 0.39\]LowerHom.0.64\[iii: b\]*A32Reis2008Immune response to rabies vaccinationCattleRabies-neutralizing antibody titer10.8 (sd, 9.5); N = 1514.4 (sd, 11.1); N = 15SMD−0.34 \[−1.06, 0.38\]HigherCont.0.36\[iii: b\]**b) HIGH RISK OF BIASi: Individualised/TreatmentRef.First authorYearConditionSpeciesOutcome measureHom.Cont.Summary effect measureEffect size (95 % CI)Direction of change favouring homeopathyDirection of effect*P*** **valueInference**\
^**a**^*A12Schütte1988Mastitis, metritis and agalactiaPigsNone useableXXXXXXXX***ii: Non-individualised/TreatmentRef.First authorYearConditionSpeciesOutcome measureHom.Cont.Summary effect measureEffect size (95 % CI)Direction of change favouring homeopathyDirection of effect*P*** **valueInference**\
**\****A42Lohr2013Diarrhoea (neonatal)CattleCure rate (Sum-score \[physical condition\])37/5042/56OR0.95 \[0.40, 2.28\]HigherCont.0.91\[iii: a\]A14Coelho2009Diarrhoea (neonatal)PigsProportion of animals without diarrhoea at the end of treatment35/355/9OR58.09 \[2.73, 1234.82\]HigherHom.0.009\[i: a\]*A41Catto2013Ectoparasite infestationCattleNone useableXXXXXXXX*A19Silva2008Ectoparasite infestationCattleNone useableXXXXXXXXA40Lotfollahzadeh2012Foot-and-mouth diseaseCattleRectal temperature38.6 (sd, 0.2); N = 5039.0 (sd, 0.1); N = 15SMD−2.16 \[−2.86, −1.47\]LowerHom.\<0.001\[i: a\]*A21Zacharias2008Gastrointestinal nematodesSheepFaecal egg count954 (sd, 1077); N = 71308 (sd, 1108); N = 7SMD−0.30 \[−1.36, 0.75\]LowerHom.0.57\[iii: a\]*A15Faulstich2006LamenessHorsesTreatment success (overall effectiveness)18/2214/19OR1.61 \[0.36, 7.12\]HigherHom.0.53\[iii: a\]A16Klocke2010MastitisCattleAbsence of clinical mastitis infection29/3232/36OR1.21 \[0.25, 5.86\]HigherHom.0.81\[iii: a\]A20Varshney2005MastitisCattleQuarter cure-rate (non-fibrosed)58/6757/96OR4.41 \[1.96, 9.93\]HigherHom.\<0.001\[i: a\]A39Braun2011Mastitis, metritis and agalactiaPigsCure rate (MMA-sum score)20/2821/32OR1.31 \[0.44, 3.92\]HigherHom.0.63\[iii: a\]*A13Beceriklisoy2008PseudopregnancyDogsTreatment \'success\' (recovery rate)30/303/8OR95.86 \[4.32, 2126.07\]HigherHom.0.004\[i: a\]A18Sandoval1998SalmonellosisBirdsNone useableXXXXXXXXA17Rocha2006Gastrointestinal nematodesSheepProportion of animals not requiring anti-helminthic treatment7/105/10OR2.33 \[0.37, 14.61\]HigherHom.0.37\[iii: b\]**iii: Non-individualised/ProphylaxisRef.First authorYearConditionSpeciesOutcome measureHom.Cont.Summary effect measureEffect size (95 % CI)Direction of change favouring homeopathyDirection of effect*P*** **valueInference**\
^**a**^A35Sommer1972InfertilityCattleNumber with infertility disorders13/409/18OR2.08 \[0.67, 6.47\]LowerHom.0.21\[iii: c\]A38Williamson1991InfertilityCattleNone useableXXXXXXXXHom. = homeopathy. Cont. = control. CI = confidence interval. sd = standard deviation. SMD = standardised mean difference. OR = odds ratioItalic text indicates trials with a potential risk of bias due to funding source (see also Table [1](#Tab1){ref-type="table"})^a^Inference from the statistical findings is given by reference to the numbered study designs in *Methods: Direction of effect of treatment/prophylaxis per trial*

### Trials with uncertain risk of bias {#Sec19}

In the absence of any trials with reliable evidence, our main attention has been forced on to the data extracted from three trials with uncertain risk of bias *and* without overt vested interest (Table [4](#Tab4){ref-type="table"}a): A32, Reis 2008 (modulation of immune response to rabies vaccination in calves); A34, Signoretti 2008 (cattle tick); A36, Soto 2008 (diarrhoea in piglets). All three trials were in the category 'non-individualised/prophylaxis/'\[A + B\] versus B' design. None of the three showed evidence of a difference between adjunctive homeopathy and active control alone, and so in each case it was statistically inconclusive whether homeopathy combined with conventional intervention was more or was less effective than conventional intervention alone -- see Table [4](#Tab4){ref-type="table"}a.

### Trials at high risk of bias {#Sec20}

Data could not be extracted from the single paper on individualised treatment. Data were extractable from 10 of the 13 relevant RCTs of non-individualised treatment; the direction of effect statistically significantly favoured homeopathy in four of the ten cases -- see Table [4b](#Tab4){ref-type="table"}. Two of these four yielded what appear to be spuriously high mean OR values (A13, Bekeriklisoy 2008: OR = 95.86; A14, Coelho 2009: OR = 58.09). Of the two RCTs of non-individualised prophylaxis (both with untreated controls), data were extractable from one (A35, Sommer 1972).

Discussion {#Sec21}
==========

This comprehensive systematic review of the peer-reviewed literature has revealed no OTP-controlled RCT of veterinary homeopathy that comprised reliable evidence. Our main conclusions from this study are therefore restricted to the findings of three RCTs, whose quality was unclear and whose methodological diversity contraindicated meta-analysis. Each of these three trials is in the category of non-individualised homeopathic prophylaxis (A32, Reis 2008; A34, Signoretti 2008; A36, Soto 2008), a prescribing approach that some homeopathic practitioners might view as controversial \[[@CR22]\]. Each of the three trials is also in the adjunctive category, and manifested statistically inconclusive findings: this result undermines the suggestion that the '\[A + B\] versus B' study design can 'generate only positive results' \[[@CR23]\].

For each of the above three trials, the uncertainty regarding risk of bias was so marked that their findings must be viewed with extreme caution. Given the lack of clarity in so many domains of assessment, this degree of concern would still apply even if we had reflected more leniently the fact that non-blinding of study personnel is a typical feature of an OTP-controlled trial. The admissible evidence in veterinary homeopathy for this study design is therefore unable to provide any compelling information about modulation of immune response in calves (A32, Reis 2008) or adjunctive prophylaxis of cattle tick (A34, Signoretti 2008) or of diarrhoea in piglets (A36, Soto 2008).

In assessing all the studies, we had reason on occasions to question the veracity of the control group as an 'active' or effective intervention (e.g. mineral or protein supplements, or naloxone in pseudopregnancy), and so raised doubts about the 'other than placebo' nature of some of the included trials. We were careful not to attribute 'equivalence' to superiority trials that found no statistically significant difference between homeopathy and active control \[[@CR16], [@CR19]\].

For OTP-controlled RCTs of non-individualised homeopathic *treatment*, there is nothing that we can reasonably conclude, given that each one of the trials was judged to be at high risk of bias. Thus, the positive inference we attributed to four trials in this category cannot be regarded as admissible evidence; the spuriously large treatment effect evidenced in two of the trials reinforces those serious concerns. It remains unknown whether non-individualised homeopathy is effective in the prophylaxis of fertility disorders in cattle. Likewise, no conclusions can be made regarding *individualised* homeopathic treatment, since the single trial in this category was of very low quality and yielded no extractable data for analysis.

Our most recent literature search, conducted during the process of the current paper's peer-review, revealed only one further OTP-controlled trial that would potentially have been eligible for inclusion \[[@CR21]\]. Notwithstanding normal concerns over the possibility that publication bias may have limited the number of 'negative' studies available, the present systematic review seems barely compromised by selection bias due to absence of relevant data.

Thus, the sum of the reliable peer-reviewed RCT evidence in veterinary homeopathy (out of 18 placebo-controlled and 20 OTP-controlled RCTs in total) comprises the two placebo-controlled trials that we previously identified \[[@CR2], [@CR3]\]. Evidence concerning the effective use of homeopathy in animals remains indecisive.

Conclusions {#Sec22}
===========

Due to their extremely poor quality, OTP-controlled trials are incapable of providing useful additional insight into the effectiveness of homeopathic treatment or prophylaxis in animals. To clarify the matter, new and substantially improved OTP-controlled research in both individualised and non-individualised veterinary homeopathy is strongly indicated.

Additional files {#Sec23}
================

Additional file 1:***PRISMA*** **2009 Checklist.** (DOC 64 kb)Additional file 2:***PRISMA*** **flowchart, illustrating records of RCTs that are eligible and ineligible for inclusion in the systematic review.** \* Records are numbered as per a previous paper published by the authors (Mathie et al., 2012) \[[@CR1]\]. *Papers presented in italics are those identified in the follow-up literature search.* Excluded papers are shown in red. \# RCT with continuous measure as main outcome (each unmarked trial has a dichotomous measure as the main outcome). (DOC 66 kb)

CAB

:   Commonwealth Agricultural Bureaux

CI

:   Confidence Interval

OR

:   Odds ratio

OTP

:   Other than placebo

PRISMA

:   Preferred reporting items for systematic reviews and meta-analyses

RCT

:   Randomised controlled trial

SMD

:   Standardised mean difference
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